Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 10, 2023AtherosclerosisOpen Access

SGLT2-inhibition increases total, LDL, and HDL cholesterol and lowers triglycerides: Meta-analyses of 60 randomized trials, overall and by dose, ethnicity, and drug type

View Full Paper
Ask AI
Bookmark
Share

Authors

LBLouise Ellegaard BechmannFEFrida EmanuelssonBNBørge G. Nordestgaard

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Bechmann et al. (2023) studied this question.

synapsesocial.com/papers/6a0c72fcd48675e49423752fhttps://doi.org/10.1016/j.atherosclerosis.2023.117236
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Empagliflozin, via Switching Metabolism Toward Lipid Utilization, Moderately Increases LDL Cholesterol Levels Through Reduced LDL Catabolism2016 · 114 citations
  2. 2Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes2020 · 1,249 citations
  3. 3Empagliflozin as Add-on to Metformin Plus Sulfonylurea in Patients With Type 2 Diabetes2013 · 376 citations
  4. 4Weight Loss and Serum Lipids in Overweight and Obese Adults: A Systematic Review and Meta-Analysis2020 · 122 citations